Our objective is to define how integrin interactions within the tumor microenvironment impact prostate cancer development, hormonal resistance, and metastasis. Our approach is to understand the normal biology of the prostate gland and its microenvironment, as well as the bone environment, to inform on the mechanisms by which tumor cells remodel and use that environment to develop, acquire hormonal resistance, and metastasize. Our research is focused in three primary areas: Developing in vitro and in vivo models that recapitulate human disease based on clinical pathology, Identifying signal transduction pathway components that could serve as both clinical markers and therapeutic targets, and Defining the genetic/epigenetic programming involved in prostate cancer development.
PhD: Harvard Medical School, 1995
MS: Colorado State University, 1982
BA: Southern Illinois University, 1980
Honors and Awards:
Outstanding Graduate Advisor Award, Michigan State University, 2010
Harvard Medical School, Cell Biology, 1997-2000
Ariad Pharmaceuticals, 1995-1997